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Abstract
Hyperinsulinaemia/euglycaemia therapy (HIET) consists of the
infusion of high-dose regular insulin (usually 0.5 to 1 IU/kg per hour)
combined with glucose to maintain euglycaemia. HIET has been
proposed as an adjunctive approach in the management of overdose
of calcium-channel blockers (CCBs). Indeed, experimental data and
clinical experience, although limited, suggest that it could be superior
to conventional pharmacological treatments including calcium salts,
adrenaline (epinephrine) or glucagon. This paper reviews the patho-
physiological principles underlying HIET. Insulin administration
seems to allow the switch of the cell metabolism from fatty acids to
carbohydrates that is required in stress conditions, especially in the
myocardium and vascular smooth muscle, resulting in an improve-
ment in cardiac contractility and restored peripheral resistances.
Studies in experimental verapamil poisoning in dogs have shown that
HIET significantly improves metabolism, haemodynamics and survival
in comparison with conventional therapies. Clinical experience
currently consists only of a few isolated cases or short series in
which the administration of HIET substantially improved cardio-
vascular conditions in life-threatening CCB poisonings, allowing the
progressive discontinuation of vasoactive agents. While we await
further well-designed clinical trials, some rational recommendations
are made about the use of HIET in severe CBB overdose. Although
the mechanism of action is less well understood in this condition,
some experimental data suggesting a potential benefit of HIET in β-
adrenergic blocker toxicity are discussed; clinical data are currently
lacking.
Introduction
Hyperinsulinaemia/euglycaemia therapy (HIET) consists of
the infusion of high-dose regular insulin (most commonly 0.5
to 1 IU/kg per hour). Of course, frequent blood glucose
monitoring by bedside capillary testing is needed to minimise
the likelihood of hypoglycaemia. Glucose infusion is adapted
to maintain euglycaemia (6 to 8 mmol/l, or 110 to 150 mg/dl).
Adults may require 15 to 30 g of glucose per hour (as
glucose 10% or more), associated with potassium supple-
ments to maintain normokalaemia.
Pathophysiological bases, as well as experimental data and
clinical observations, suggest that HIET might be useful in
cases of severe overdose of calcium-channel blockers
(CBBs). Conventional measures that consist of intravenous
fluids, calcium salts, dopamine, dobutamine, noradrenaline
(norepinephrine), phosphodiesterase inhibitors or glucagon
often fail to improve the haemodynamic condition of the
patient, so that more invasive procedures such as intra-aortic
balloon counterpulsation or extracorporeal circulatory support
may be needed [1-3]. Until now, HIET has mainly been used
as a rescue therapy and as an alternative to invasive
procedures. However, HIET seems to ensure a more
favourable energetic balance in the myocardium than other
conventional treatment. It has few side effects provided that
glycaemia is frequently checked, and it uses only widely
available and relatively inexpensive medications. Because
HIET failures have mainly been reported when it was
introduced late as a rescue measure, it seems rational to
propose its earlier use in patients with hemodynamic
compromise associated with CCB overdose.
Some promising experimental data also suggest potential for
HIET in overdose of β-blockers but clinical experience is
lacking as yet.
Pathophysiological bases
Severe CCB toxicity consists mainly of hypotension or shock
due to cardiac dysfunction (bradycardia, conduction delay
and negative inotropy) and peripheral vasodilation [1,2]. Poor
tissue perfusion results in metabolic lactic acidosis. The
cardiovascular disorders related to CCB toxicity are thought
to be a direct consequence of an excessive blockade of the
L-type calcium channel in myocardial and vascular smooth
muscle membranes: by preventing calcium influx into cells,
CCBs decrease cardiac inotropy, dromotropy and
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chronotropy, as well as vascular tone. Conventional treat-
ments of CCB overdose consist of attempts to increase
transmembrane calcium flow either by increasing extracellular
calcium concentration (calcium salts) or by increasing intra-
cellular cAMP concentration, which can be achieved by
adenylate cyclase stimulation (with adrenaline or glucagon) or
phosphodiesterase inhibition (with amrinone or milrinone) [3].
None of these antidotes has been shown to reverse CCB
cardiovascular toxicity reliably: no controlled clinical trial has
been conducted and treatment successes or failures have
been reported in almost equal measure [4-9].
Hyperglycaemia is another common feature in CBB poisoning
[10-13] and can even result from therapeutic doses [14].
Indeed, blockade of L-type calcium channels impairs insulin
release by the pancreatic β-islet cells [15] and impairs
glucose uptake by tissues by altering sensitivity to insulin
[16,17]. Hypoinsulinaemia and insulin resistance could be
cornerstones in the pathophysiology of CCB cardiovascular
toxicity, beside the direct effect of calcium channel blockade.
Indeed, under normal aerobic conditions, myocardial cells
oxidise free fatty acids (non-esterified fatty acids) as the main
energy substrate. Conversely, in poor haemodynamic or
aerobic conditions (such as those induced by CCB toxicity),
myocardial cells switch to glucose utilisation for the main fuel.
However, the decreased perfusion impairs glucose delivery to
tissues. Furthermore, hypoinsulinaemia and insulin resistance
obviate the uptake of glucose, especially by myocardial and
vascular muscle cells, thereby preventing its adequate use as
main energy substrate. The lack of fuel and energy stores
further compromises the cardiovascular condition already
impaired by the blockade of calcium channels. These
mechanisms give rise to the hypothesis that high-dose insulin
therapy could be beneficial in the management of CCB
overdose by overcoming hypoinsulinaemia and insulin
resistance and thereby breaking the vicious circle of
haemodynamic deterioration leading to shock and death.
Although both animal experience and clinical observations
seem to confirm that HIET is able to improve inotropy and
peripheral vascular resistance, to reverse acidosis and to
increase survival, the exact mechanism underlying these
actions still remains controversial. Nevertheless, because the
beneficial haemodynamic effects of insulin are probably
related to changes in cellular metabolism, they are
unsurprisingly delayed, frequently occurring within 30 to 45
minutes of starting HIET.
Supporting experimental data
A model using verapamil toxicity in dogs has been used
because it produces comparatively greater haemodynamic
depression in vivo than other CCBs.
Kline and colleagues [18] demonstrated that HIET improved
heart function in anaesthetised dogs in which severe CCB
toxicity (hypotension or complete atrioventricular dissociation)
was induced by the intravenous (i.v.) administration of
verapamil. In this model, various treatment protocols were
compared: (1) normal saline (2.0 ml/min); (2) adrenaline
(starting at 1.0 µg/kg per minute, titrated to maintain left
ventricular pressure at basal values); (3) HIET (4.0 IU/min
insulin with 20% glucose, arterial glucose clamped); or (4)
glucagon (0.2 to 0.25 mg/kg bolus followed by an infusion at
150 µg/kg per minute). Another study added a fifth treatment
group with calcium chloride (20 mg/kg bolus, then 0.6 mg/kg
per hour) [19]. Treatments were continued until death or
240 minutes. Surviving animals then received a 3.0 mg/kg
additional bolus of verapamil. All controls died within
85 minutes. Four out of six survived after adrenaline, three out
of six after glucagon and calcium chloride, and six out of six in
the HIET group. All treatments tended to improve haemo-
dynamic status. Although HIET did not significantly increase
mean blood pressure and heart rate, it significantly improved
maximum elastance at end systole (EES), left ventricular end
diastolic pressure (LVEDP) and coronary artery blood flow
compared with other treatments. Only the six HIET-treated
animals survived the additional bolus of verapamil.
The same group of authors subsequently performed several
studies to elucidate the underlying mechanisms of these
HIET-related beneficial effects. They demonstrated that
during verapamil toxicity, the myocardial glucose uptake
doubled despite a decrease in cardiac work, and the
myocardial respiratory quotient increased [19]. Net
myocardial lactate uptake also increased significantly,
excluding myocardial ischaemia. However, plasma insulin
concentration did not increase despite hyperglycaemia. HIET
produced a larger improvement in myocardial contractility and
ratio of myocardial oxygen delivery to work than did calcium
chloride, adrenaline or glucagon, and these effects, which
were correlated with the myocardial glucose uptake, probably
explain the improved survival even when an additional bolus
of verapamil was administered [19].
For better simulation of an oral overdose, another canine
model of verapamil toxicity was developed in which
cardiogenic shock was induced in awake dogs by graded
intraportal infusion of verapamil [20]. Animals were treated
with one of the following: (1) saline (3.0 ml/kg per minute);
(2) adrenaline (5 µg/kg per minute); (3) glucagon (10 µg/kg
per minute); or (4) HIET (1 IU/min with glucose to clamp
arterial glycaemia to ±10% of basal concentrations). One
dog died early with glucagon treatment before the first death
in the saline-treated group. Once again, insulin provided
superior improvement in systolic and diastolic heart function
than other treatments. The myocardial efficiency (ratio of left
ventricular minute work to myocardial oxygen consumption)
also increased. Conversely, both adrenaline and glucagon
decreased mechanical efficiency in comparison with saline
controls. In contrast with adrenaline and glucagon, HIET did
not improve cardiac function by increasing catecholamine
concentration but rather through direct effects on myocardial
metabolism. HIET increased myocardial lactate consumptionPage 3 of 6
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but not glucose uptake, whereas both adrenaline and
glucagon increased myocardial fatty acid consumption
without increasing lactate uptake.
In the same model, Kline and colleagues [16] have further
studied the effect of insulin treatment on myocardial use of
lipid and carbohydrate. HIET alone induced sevenfold and
threefold increases in myocardial glucose and lactate
extractions, respectively. However, no change in myocardial
blood flow or EES was detected. Verapamil toxicity was
shown to produce a decrease in myocardial extraction of free
fatty acids without a change in arterial concentration of free
fatty acids, whereas myocardial glucose extraction was
doubled with an increase in arterial glucose. No change in
myocardial blood flow was observed, but EES decreased. In
comparison with saline controls, HIET improved the EES and
survival of verapamil-intoxicated dogs, but neither myocardial
glucose nor lactate extraction increased significantly.
These studies in dogs show that verapamil toxicity produces
a decrease in myocardial contractile efficiency by a
combination of metabolic synergistic effects and calcium
channel blockade. Although the availability of free fatty acids
is maintained, myocardial extraction is decreased, making the
heart dependent on carbohydrates as an energy supply. In
contrast, verapamil toxicity results in both blockade of insulin
release by pancreatic cells and systemic insulin resistance
[17] that impedes insulin-stimulated myocardial glucose
uptake and renders the tissues’ carbohydrate uptake
dependent on glucose concentration.
In verapamil toxicity, HIET increases myocardial contractility,
but this effect does not seem to be related to an increase in
glucose transport. Whether these effects can be extrapolated
to the toxicity of all other CCBs, including dihydropyridine
and benzothiazepine agents, is unknown.
Supporting clinical data
Adult clinical experience
In 1999, Yuan and colleagues [21] reported the case of a 31-
year-old male who developed sustained hypotension,
bradycardia and complete heart block after ingesting an
overdose of extended-release verapamil. The ejection fraction
was estimated at 10% on the basis of an echocardiogram.
Because the condition failed to improve with respiratory
support, activated charcoal, i.v. fluids, calcium chloride,
glucagon and atropine, HIET was started (10 IU of insulin
bolus plus 25 g of glucose, followed by a continuous insulin
infusion of up to 4 to 10 IU/h, along with 8 to 15 g/h
glucose). Blood pressure improved within 15 minutes, the
patient converted to normal sinus rhythm within an hour and
ejection fraction was measured at 50% 3 hours later.
However, dopamine had to be infused because of persistent
oliguria. Dopamine and insulin infusions were discontinued at
18 and 22 hours, respectively. The same paper documented
the clinical courses of two other adult patients with verapamil
overdose and one patient with amlodipine–atenolol overdose
who developed hypodynamic circulatory shock unresponsive
to conventional treatment. HIET also produced an improve-
ment in hemodynamic status and all patients survived.
Two other cases of HIET use were reported by Boyer and
Shannon [22]. A 48-year-old man was admitted with
haemodynamic instability after ingesting an unknown amount
of extended-release diltiazem; he failed to respond to calcium,
i.v. fluids, dopamine and dobutamine. An insulin infusion
(0.5 IU/kg per hour plus 10 g/h glucose) markedly improved
the blood pressure and allowed the discontinuation of
vasoactive agents within 30 minutes. The insulin infusion was
maintained for 5 hours. The other patient was a 34-year-old
woman who developed shock 1 hour after ingesting
amlodipine tablets. Conventional therapies failed to improve
haemodynamic condition so that insulin infusion at the same
rate was started. Although the patient was non-diabetic, her
initial capillary glucose was 325 mg/dL: it was cautiously
measured every 15 to 30 minutes but she never needed
supplemental glucose. Haemodynamic status improved
within 30 minutes. Dopamine, noradrenaline and glucagon
were stopped 45 minutes after starting HIET, which was
discontinued 6 hours later.
Similar cases have been reported by Rasmussen and
colleagues [23], Marques and colleagues [24], Ortiz-Munoz
and colleagues [25] and Place and colleagues [26], including
elderly patients with previous cardiovascular disease, and
have been collected with more details elsewhere [27,28].
The case reported by Min and Deshpande [29] is especially
interesting because haemodynamic data were obtained from
a right heart catheter before and during HIET in a 59-year-old
female after ingestion of slow release diltiazem together with
sedatives. HIET (0.5 IU/kg per hour and 50% glucose
infusion) was started because the patient remained
dependent on the infusion of vasoactive drugs after 15 hours
of treatment (i.v. fluids, adrenaline, noradrenaline and
vasopressin). An increase in mean arterial pressure was
observed within 30 minutes of starting HIET, and all
vasoactive agents were discontinued within 60 minutes. The
predominant haemodynamic effect of HIET surprisingly
seemed to be an increase in peripheral vascular resistance
rather than an inotropic effect.
Whatever the main haemodynamic effect involved, these
observations support the value of HIET in patients with CCB
intoxication and circulatory compromise and suggest that this
therapy should probably be considered earlier in the
management of the condition rather than being used as a
rescue option. Indeed, some cases in which HIET was
introduced late in the treatment and failed to improve the
patient’s condition have also been reported [30-32]. The
effectiveness of HIET is often limited to an improvement of
hypotension and acidosis that is observed within 30 to
Available online http://ccforum.com/content/10/3/21245 minutes of starting insulin administration. Direct actions on
bradycardia and cardiac conduction are variable and are
hardly differentiated from effects due to the improvement of
haemodynamic status.
Paediatric clinical experience
Yuan’s series [21] included the case of a 14-year-old girl who
developed hypotension, bradycardia and complete heart
block after ingesting SR verapamil. Initial treatment with
activated charcoal, calcium gluconate and atropine provided
only a transient response. HIET (insulin 10 IU bolus, followed
by a continuous infusion of 12 to 20 IU/h with glucose 6 g/h)
was associated with an increase in blood pressure, so that no
other vasoactive medication was required. Insulin and
glucose were discontinued at 9 and 12 hours, respectively.
Meyer and colleagues [33] also reported the history of a 13-
year-old girl intentionally poisoned with SR verapamil, who
developed hypotension and bradycardia. Calcium chloride,
glucagon, adrenaline and noradrenaline provided only a
transient improvement. HIET (insulin 0.1 IU/kg plus glucose
0.5 g/kg as a bolus, followed by continuous infusion) was
started and was accompanied by marked haemodynamic
improvement, so that vasoactive drugs were discontinued
within 90 minutes. HIET was maintained for 26 hours.
Morris-Kukoski and colleagues [34] reported the case of a
5-month-old female infant who was inadvertently given 20 mg
of nifedipine and rapidly developed hypotension. Despite
ventilatory assistance, calcium chloride, glucagon, dopamine,
adrenaline, phenylephrine and milrinone, severe hypotension
persisted and profound acidosis developed. HIET (1 IU/kg per
hour) improved the patient’s blood pressure, so that glucagon
and phenylephrine were discontinued 30 minutes and 2 hours
later, respectively. However, adrenaline, dopamine and
milrinone had to be maintained for 72 to 90 hours. Insulin
administration was discontinued after 96 hours. Progress was
complicated by anuric renal failure that resolved within 30 days.
Adverse effects
Hypoglycaemia and hypokalaemia are the main adverse
effects that can be expected during insulin infusion.
Hypoglycaemia
Some patients with hyperglycaemia related to CBB toxicity
did not require glucose supplementation during insulin
infusion [22]. Administration of glucose should therefore be
individually titrated according to frequent determinations of
glycaemia, rather than by following standard protocols.
Special attention is required in patients with altered mental
status, due either to poor haemodynamic condition or to co-
ingestion of sedative drugs, in whom clinical signs of
hypoglycaemia may be masked.
Hypokalaemia
Most patients do not develop significant hypokalaemia.
Actually, acidosis due to haemodynamic compromise may be
accompanied by mild hyperkalaemia due to an outward shift
of potassium, and HIET will only shift the potassium back into
cells. In Yuan’s series [21], it was observed in only three out of
five cases, including one with hydrochlorothiazide co-ingestion.
It was not accompanied by any complication. Hypokalaemia is
thought to be related to intracellular transfer of potassium
during insulin infusion. Supplementation is usually not required
in asymptomatic patients because potassium stores are
normal. It has even been suggested that mild hypokalaemia
may offer benefit by promoting cellular calcium entry and
increasing the inotropic effect of insulin [21,24].
Recommendations for the use of HIET in CCB
poisoning
Although there is wide variation in insulin dosing in the cases
reporting the use of HIET in CCB overdose and in the
duration of treatment, rational recommendations could
currently consist of the administration of 1.0 IU/kg i.v. as a
bolus, followed by 0.5 IU/kg per hour i.v. Glycaemia must be
checked at least once every 30 minutes and hypertonic
glucose must be infused to maintain blood glucose in the
upper normal range. Up to 20 to 30 g/h may be needed in
adults. Supplemental potassium is required only to prevent
severe hypokalaemia. The duration of HIET should be guided
by the clinical response, especially haemodynamic parameters:
the goal should be haemodynamic stability after the
withdrawal of vasoactive agents. Such rational recommen-
dations have already been formulated by Boyer and
colleagues [35] but unfortunately have never been validated
prospectively in clinical trials.
HIET should not replace other therapeutic approaches but
should be considered as an adjunct. However, it must be
kept in mind that delaying its use in severe CCB poisoning is
likely to reduce its clinical benefit markedly.
Could HIET also be valuable in β β-blocker
overdose?
Some experimental data from animal studies suggest that
HIET could be of benefit in β-blocker toxicity and that this
possibility certainly deserves further evaluation and
comparison with commonly recommended therapies.
Reikeras and colleagues have studied the haemodynamic
[36] and metabolic [37] effects of small and high doses of
insulin during β-receptor blockade induced by 0.5 mg/kg
propranolol in dogs. Insulin (0.5 IU/kg i.v. bolus followed by a
continuous infusion of 0.5 IU/kg per hour and a 300 IU high-
dose bolus 30 minutes later) was administered in association
with glucose and potassium to maintain physiological blood
concentrations. Propranolol depressed cardiac performance
(increased LVEDP, decreased maximum rate of left
ventricular pressure rise, left ventricular dP/dtmax, stroke
volume and cardiac output). Only 5 minutes after low-dose
insulin, performance parameters significantly improved. The
high-dose insulin further improved heart function. Peripheral
Critical Care    Vol 10 No 3 Lheureux et al.
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of compensatory vasoconstriction when cardiac output
improved. Inotropic effects of insulin seem to be dose
dependent and unrelated to adrenergic mechanisms.
In this canine model, β-receptor blockade was accompanied
by a significant decrease in myocardial blood flow and
oxygen consumption. Arterial concentrations and myocardial
uptake of free fatty acids were reduced, whereas arterial
concentrations and myocardial uptake of glucose and lactate
remained unchanged. Improvement of heart performance
induced by low-dose insulin was not accompanied by an
increase in myocardial oxygen consumption. Myocardial
uptake of glucose increased significantly, whereas uptake of
lactate and free fatty acids was unchanged. Myocardial blood
flow and oxygen consumption also remained unaltered after
the high dose of insulin despite the considerable
improvement in heart performance, as well as arterial
concentrations and myocardial uptake of glucose, lactate and
free fatty acids. The effect of insulin on heart performance
thus seems to be independent of effects on substrate
metabolism.
In a canine model of heart supported by cardiopulmonary
bypass, high-dose insulin (aortic root bolus of 1,000 IU
insulin, with a glucose clamp maintained at physiological
levels) reversed the negative inotropic effect of propranolol
(0.2 mg/kg) to 80% of control function and normalised heart
rate without augmenting oxygen utilisation [38].
In another model [39], dogs received intravenous propranolol
(0.25 mg/kg per minute) until decreased contractility and
hypotension were observed. Half an hour later, animals were
treated with one of the following: (1) saline (control), (2) HIET
(4 IU/min insulin with glucose clamped at ±10% of the
baseline values by the infusion of 50% glucose), (3) glucagon
(50 µg/kg bolus and 150 µg/kg per hour infusion) or (4)
adrenaline (1 µg/kg per minute). They were monitored until
death or for 240 minutes. All animals died in the control
group, whereas six out of six HIET-treated, four out of six
glucagon-treated and one out of six adrenaline-treated
animals survived. HIET also provided a sustained increase in
blood pressure and cardiac performance (decreased LVEDP,
increased stroke volume and cardiac output) compared with
glucagon or adrenaline. However, HIET had no effect on
heart rate and conduction. Vasodilation could result from
improved cardiac function and decreased compensatory
vasoconstriction. HIET-treated animals were also
characterised by increased myocardial glucose uptake and
decreased serum potassium [39].
HIET could thus offer a potential benefit in β-blocker
overdose as well as in CBB toxicity. To our knowledge, no
clinical experience of pure β-blocker overdose has been
reported, but several case reports involve mixed intoxications
involving both CCBs and β-blockers [21,25].
Conclusion
There is growing experimental and clinical evidence of the
value and the safety of HIET in the management of CCB
poisoning. Although the mechanism of this beneficial action is
not fully explained, HIET should be considered in patients
with CBB-induced cardiovascular compromise. Although not
effective in all cases, HIET often improves arterial blood
pressure, myocardial contractility and metabolic acidosis,
while failing to correct bradycardia or conduction defects,
including heart block and intraventricular conduction delay.
Of course, additional clinical research and prospective clinical
studies are needed to confirm the safety and efficacy of HIET
and to support more formal guidelines and therapeutic
regimens, but some rational recommendations can be made
on the basis of the available data. Although HIET is still often
presented as a rescue adjunct in patients who fail to respond
to conventional treatments including calcium salts, glucagon
or catecholamine infusion, the delayed onset of its action (30
to 45 minutes) required for metabolic actions probably justifies
an earlier introduction in treatment protocols in combination
with supportive measures. More invasive procedures to assist
circulation could thereby be avoided. Careful monitoring of
blood glucose and serum potassium concentrations is
required to prevent adverse effects.
Some animal data suggest that HIET could be also beneficial
in β-blocker poisoning, but more data are required before this
therapy can be evaluated in this indication.
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